Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infertility and inflammatory urogenital diseases in metabolic syndrome
2011-000624-16Phase 2Terminated
- Sponsor
- Justus Liebig University Giessen
- Start
- Sep 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of atorvastatin, simvastatin, fenofibrate, ramipril, fosinopril and 6 more in cardiometabolic risk (CMR), male infertility, urogenital disease and 1 more, sponsored by Justus Liebig University Giessen. Primary endpoint: Change in sperm concentration at 12 months. Started Sep 2011; status: terminated.
02
Drugs
atorvastatinsimvastatinfenofibrateramiprilfosinopril
03
Conditions
cardiometabolic risk (CMR)male infertilityurogenital diseaseinflammatory disease of the urogenital tract
Beyond the preview
Go deeper on 2011-000624-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000624-16.